Akero Therapeutics (AKRO)
(Delayed Data from NSDQ)
$23.02 USD
+1.69 (7.92%)
Updated Jun 7, 2024 04:00 PM ET
After-Market: $22.99 -0.03 (-0.13%) 7:58 PM ET
3-Hold of 5 3
D Value F Growth B Momentum F VGM
Brokerage Reports
0 items in cart
Akero Therapeutics, Inc. [AKRO]
Reports for Purchase
Showing records 101 - 105 ( 105 total )
Company: Akero Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Healthcare - Earnings Recap: The More Analysis, The Merrier, Especially When Data-Driven
Provider: Roth Capital Partners, Inc.
Analyst: RAHIMI Y
Company: Akero Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Akero Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
2Q19 - Holding Well Through the Rough NASH Sentiment
Provider: Roth Capital Partners, Inc.
Analyst: RAHIMI Y
Company: Akero Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
We are initiating coverage with a Buy rating and $34 price target
Provider: Roth Capital Partners, Inc.
Analyst: RAHIMI Y
Company: Akero Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.